9.85

5.01% 0.47

After Hours: 9.99 0.14 +1.42%

Corvus Pharmaceuticals Inc (CRVS)

Overview News Price History Option Chain Financials Discussions Forecast

Corvus Pharmaceuticals Inc stock is traded at $9.85, with a volume of 849.13K. It is up +5.01% in the last 24 hours and down -23.94% over the past month. Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Previous Close:

$9.38

Open:

$9.49

24h Volume:

849.13K

Relative Volume:

0.69

Market Cap:

$828.59M

Revenue:

Net Income/Loss:

$-44.17M

P/E Ratio:

-18.73

EPS:

-0.526

Net Cash Flow:

$-35.14M

1W Performance:

-3.53%

1M Performance:

-23.94%

6M Performance:

-34.81%

1Y Performance:

+28.09%

1-Day Range:

$9.36

$10.07

1-Week Range:

$9.21

$10.71

52-Week Range:

$6.39

$26.95

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name

Corvus Pharmaceuticals Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(650) 900-4520

Address

901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA

Employee

Twitter

Next Earnings Date

2026-11-03

Latest SEC Filings

CRVS's Discussions on Twitter

Compare CRVS vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRVS Corvus Pharmaceuticals Inc	9.85	828.59M	0	-44.17M	-35.14M	-0.526
VRTX Vertex Pharmaceuticals Inc	508.74	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.35	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.50	53.23B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.30	42.34B	5.76B	514.49M	1.10B	4.4813

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-26	Initiated	Goldman	Buy
Oct-13-25	Initiated	Barclays	Overweight
Jan-02-25	Initiated	H.C. Wainwright	Buy
Aug-18-23	Initiated	Oppenheimer	Outperform
Dec-01-21	Resumed	Jefferies	Buy
May-27-21	Initiated	Cantor Fitzgerald	Overweight
Feb-10-21	Downgrade	Mizuho	Buy → Neutral
Sep-12-19	Initiated	Mizuho	Buy
May-29-19	Initiated	ROTH Capital	Buy
Aug-24-17	Upgrade	Credit Suisse	Underperform → Neutral
May-01-17	Downgrade	Credit Suisse	Neutral → Underperform
Apr-18-16	Initiated	Credit Suisse	Outperform
Apr-18-16	Initiated	Guggenheim	Buy

View All

Corvus Pharmaceuticals Inc Stock (CRVS) Latest News

Oct 12, 2026

Corvus Pharma Q2 2026 Earnings Call Transcript - Benzinga

Oct 12, 2026

Oct 11, 2026

Other investing cash flow items (total) of Corvus Pharmaceuticals, Inc. – FWB:C17 - TradingView

Oct 11, 2026

Oct 09, 2026

Corvus Pharmaceuticals Inc. R (C17.HA) analyst ratings, estimates and forecasts - Yahoo Finance UK

Oct 09, 2026

Sep 30, 2026

Corvus Pharma Com (CRVS-Q) Stock Price and News - The Globe and Mail

Sep 30, 2026

Corvus Pharmaceuticals Announces Initiation of Phase 1b - GlobeNewswire

Sep 30, 2026

One drug is now in trials for four conditions, including a skin disease. - stocktitan.net

Sep 30, 2026

Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa - Yahoo! Finance Canada

Sep 30, 2026

Corvus Pharmaceuticals,Primary Endpoint Is - Moomoo

Sep 30, 2026

Sep 29, 2026

Enterprise value of Corvus Pharmaceuticals, Inc. – HAN:C17 - TradingView

Sep 29, 2026

Sep 25, 2026

Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In? - Yahoo! Finance Canada

Sep 25, 2026

Sep 18, 2026

CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits

Sep 18, 2026

Sep 10, 2026

Corvus Pharmaceuticals at cantor global healthcare: pipeline bets widen By Investing.com - Investing.com South Africa

Sep 10, 2026

Corvus Pharmaceuticals at cantor global healthcare: pipeline bets widen By Investing.com - Investing.com India

Sep 10, 2026

Corvus Pharmaceuticals at cantor global healthcare: pipeline bets widen By Investing.com - Investing.com Canada

Sep 10, 2026

Sep 09, 2026

Trial Results Published Could Be A Game Changer For Corvus Pharmaceuticals (CRVS) - simplywall.st

Sep 09, 2026

Sep 03, 2026

Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference - marketscreener.com

Sep 03, 2026

A biotech company's live healthcare talk is set for Sept. 10. Its webcast stays online 90 days. - Stock Titan

Sep 03, 2026

Sep 02, 2026